Jabri Amina M, Assad Hayder Ch, Al-Jumaili Ali Azeez
University of Kufa College of Pharmacy, Najaf, Iraq.
University of Baghdad College of Pharmacy, Iraq.
Saudi Pharm J. 2020 Apr;28(4):473-479. doi: 10.1016/j.jsps.2020.02.009. Epub 2020 Feb 17.
This study aimed to explore the cardiologist adherence with ACC/AHA guidelines on discharge medications for patients admitted with acute coronary syndrome (ACS), assess the predictors of cardiologist non-adherence and measure the impact of pharmacist intervention on improving guideline adherence.
The study included two consecutive phases: observation and intervention. It was carried out at Al-Najaf Center for Cardiac Surgery and Catheterization, Iraq, from August through December 2018. In the observation phase, medical records were reviewed retrospectively in order to assess the adherence to guideline. The intervention phase was performed prospectively by the clinical pharmacist, who conducted interventions including auditing, feedback and discussion with every prescriber. The reference of the recommendations was the guideline of American Heart Association/American College of Cardiology guideline (AHA/ACC). The primary outcome was the proportion of patients discharged with optimal treatment. Independent T-test was used to measure the difference in the means of age between the two patient groups. For categorical variables (gender, diagnosis, and comorbidities), chi-square test was used. Binary logistic regression was used to identify patient and disease characteristics associated with receiving optimal discharge regimen.
The observation phase included 100 patients with ACS, while the intervention phase included 105 patients. A total of 50 interventions were performed by pharmacist, of which adding necessary medication was the most frequent (88%), followed by dose optimization (10%), and removing medication duplication (2%). Seventy-four percent of the provided recommendations were accepted by the cardiologists. Pharmacist intervention caused significant (P-value < 0.05) improvement (increasing) in the prescribing of β-blockers, ACE inhibitors/ARBs, statins, and the proportion of patients who received all optimal five therapies (from 35% in observation phase to 80% after intervention).
This study showed that pharmacist intervention had a considerable positive impact on the cardiologist prescribing pattern of the essential discharge medications for patients with ACS which could improve patient clinical outcomes.
本研究旨在探讨心脏病专家对急性冠状动脉综合征(ACS)患者出院用药遵循美国心脏病学会(ACC)/美国心脏协会(AHA)指南的情况,评估心脏病专家不遵循指南的预测因素,并衡量药师干预对提高指南遵循率的影响。
该研究包括两个连续阶段:观察阶段和干预阶段。研究于2018年8月至12月在伊拉克纳杰夫心脏外科和导管插入中心进行。在观察阶段,对病历进行回顾性审查以评估对指南的遵循情况。干预阶段由临床药师前瞻性地进行,临床药师开展的干预措施包括审核、反馈以及与每位开处方者进行讨论。推荐的参考依据是美国心脏协会/美国心脏病学会指南(AHA/ACC)。主要结局是接受最佳治疗出院的患者比例。采用独立样本t检验来衡量两组患者年龄均值的差异。对于分类变量(性别、诊断和合并症),采用卡方检验。采用二元逻辑回归来确定与接受最佳出院治疗方案相关的患者和疾病特征。
观察阶段纳入100例ACS患者,干预阶段纳入105例患者。药师共进行了50次干预,其中最常见的是添加必要药物(88%),其次是剂量优化(10%),以及消除药物重复(2%)。心脏病专家接受了74%的所提供建议。药师干预使β受体阻滞剂、血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂、他汀类药物的处方量显著增加(P值<0.05),并且接受全部五项最佳治疗的患者比例也显著增加(从观察阶段的35%增至干预后的80%)。
本研究表明,药师干预对心脏病专家为ACS患者开具基本出院药物的处方模式产生了相当大的积极影响,这可能改善患者的临床结局。